Abstract: Being one of the most lethal cancers that exhibit high levels of heterogeneity, hepatocellular carcinoma (HCC) is associated with diverse oncogenic pathways underpinned by varied driver genes. HCC can be induced by different etiological factors including virus infection, toxin exposure or metabolic disorders. Consequently, patients may display varied genetic profiles, and may respond differently to the treatments involving inhibition of target pathways. These DNA/RNA mutations, copy number variations, chromatin structural changes, aberrant expression of non-coding RNAs and epigenetic modifications were considered as biomarkers in the application of precision medication. To explore how genetic testing could contribute to early diagnosis, prognosis, treatment and postoperative monitoring of HCC, we conducted a systematic review of genetic markers associated with different pathologies. Moreover, we summarized on-going clinical trials for HCC treatment, including the trials for multiple kinase inhibitors and immune checkpoint blockade (ICB). The efficacy of ICB treatment in HCC is not as good as what was observed in lung cancer and melanoma, which might be due to the heterogeneity of the microenvironment of the liver.

Keywords: genetic biomarkers, hepatocellular carcinoma, genomic sequencing, clinical trials

Introduction

Liver cancer is considered to be the fourth most lethal cancer globally, and hepatocellular carcinoma (HCC) accounts for 75–85% of liver cancer cases. In addition to the high mortality rate, the prognosis and treatment of HCC are suboptimal, most of the patients reach malignancy within a year of initial diagnosis. The survival statistics of the American cancer society from 2008 to 2014 showed that the the overall 5-year survival rate was 18% for liver cancer patients, but the 5-year survival rate for patients with distant metastasis was only 2%. In great contrast, among early-stage HCC patients who were diagnosed and treated before extrahepatic metastasis, the 5-year survival rate would be increased to 31%. To improve HCC early diagnosis rate, HCC biomarkers with higher sensitivity and specificity are required. Postoperative monitoring, which aims to evaluate disease progression and predict cancer recurrence, also heavily relies on the exploration of HCC biomarkers. Recently, targeted therapy, immune checkpoint blockade therapy, and combinational therapy showed promising efficacy in clinical trials. Biomarkers also play an important role in the design of personalized treatment plans. In the new era of genomic oncology, genetic biomarkers are becoming the core of cancer biomarkers. To bring a panoramic view of HCC genetic markers...
to academic and clinical experts, we conducted a systemic review of these genetic biomarkers for HCC early diagnosis, prognosis, treatment and postoperative monitoring.

Etiology And Pathogenesis
The primary risk factors of HCC are chronic hepatitis B and hepatitis C virus infection, alcohol consumption, non-alcoholic fatty liver disease, exposure to dietary aflatoxin, genetic hemochromatosis, and metabolic disorders. The resulting chronic liver inflammation may develop to severe liver fibrosis and cirrhosis, which were predispositions of HCC. It was reported that up to 90% of HCC cases occurred on the background of liver cirrhosis or fibrosis. Increased production of ROS was predicted to cause the accumulation of oxidative stress and DNA instability, which were accompanied by hepatocytes proliferation, telomeres shortening, and chromosomal alterations. These processes were associated with tumor development in fibrosis according to early studies. Interestingly, each HCC risk factor is involved in differed signaling pathways during carcinogenesis as Figure 1 shows, and the resulting HCC patients often exhibit distinct genomic profiles.

Hepatitis B Virus Infection
In HBV endemic regions such as Asia-Pacific and sub-Saharan Africa, HBV infection accounts for 75–90% of HCC incidences. Once entered the host cell, the HBV DNA transcribes to 4 viral mRNA for 7 HBV proteins, one of which is the 17kDa polypeptide HBV X (HBx) that regulates cell proliferation and apoptosis by modulating Wnt/β-catenin expression. As Figure 1 shows, overexpression of HBx could also activate NF-κB to block tumor necrosis factor-α (TNFα)− and FAS-mediated apoptosis. In addition, both HBV and HCV can cause mitochondrial

Figure 1 Signaling pathways affected by the etiological factors of HCC. HBV/HCV infection, alcohol consumption, aflatoxin exposure, NAFLD and metabolic disorders may trigger HCC by manipulating diverse signaling pathways. Abbreviations: ADGRB1, adhesion G protein-coupled receptor B1 gene; AKT, protein kinase B; CPT2, carnitine o-palmitoyltransferase 2 gene; ER, endoplasmic reticulum; FAS, fas receptor; KCTD17, potassium channel tetramerization domain containing 17; NF-κB, nuclear factor-κB; NANOG, homeobox protein; PHLP2, PH domain and leucine-rich repeat protein phosphatase; ROS, reactive oxygen species; STAT3, signal transducer and activator of transcription 3; TLR4, toll-like receptor 4; TNFα, tumor necrosis factor; TWIST1, twist-related protein 1; UPR, unfolded protein response.
stress and increase reactive oxygen species (ROS) levels, which triggers endoplasmic reticulum (ER) stress and the unfolded protein response (UPR), leading to autophagy promoted cell survival and virus persistence.  

Given that different risk factors induce HCC through varied mechanisms, the genomic profiles of patients affected by those risk factors may differ. An early study screened biomarkers for HBV induced HCC and identified 7 up-regulated genes in those patients including RPS5, KRT8, CFLAR, ATP5F1, IGFBP2, MAP3K5, and MMP9. The genes regulate diverse cellular processes ranging from protein synthesis to cytoskeleton organization. More recent research showed that CCND1, BCL2, Mcl-1, NFKB1 and SOCE were also up-regulated in HBV induced HCC. Additionally, one whole-exome sequencing study reported that TP53, CTNNB1, RB1, AXIN1, SELPLG, and FGFI9 appear to be the candidates of driver mutation genes for HBV induced HCC. The unique genomic profile of HBV induced HCC can be applied to the early diagnosis of HCC, which attributes to the implement of precise curative treatment that may improve the survival of patients.

**Hepatitis C Virus Infection**

Being the second most common cause of HCC worldwide, HCV infection is responsible for at least 10% of HCC incidences. HCV infection is a major cause of HCC in Western countries, Africa and Japan. The core proteins of HCV such as E2, NS5A, and NS5B were shown to interfere with the E2F1 pathway and RAF/MAPK/ERK kinase pathways (Figure 1), by which they may modulate cell proliferation and tumor development. The other HCV produced protein, NV5a, was reported to inhibit the p53 pathway, which consequently modulates cell cycle.

Apart from carcinogenesis, data suggest that HCV induced HCC can be distinguished from HBV induced HCC based on the genomic profile of the patients. An early study compared the gene expression pattern of HCV and HBV induced HCC, they concluded that different genes were up-regulated in the two scenarios. Unlike the HBV infected population, VIM, ACTB, GAPD, and CD58 were up-regulated in HCV induced HCC cases. A later study identified 40 up-regulated genes in HCV triggered HCC cases compared to the controls, including RYBP, ATP1B3, TMC, ZNF567, GPR108, CD19. These studies identified potential biomarkers for HCV induced HCC, which are crucial to the design of treatment strategy for precision medicine.

**Alcohol Consumption**

Alcohol-related cirrhosis is the third most common trigger of HCC worldwide, which appears to correlate with alcohol consumption behavior. Alcohol intake may increase the production of iron-induced reactive oxygen species (ROS), which would interfere with DNA repair mechanisms (Figure 1). Moreover, acetaldehyde is formed during ethanol metabolism, the accumulation of acetaldehyde has negative effects on DNA and proteins.

Patients carrying alcohol-related HCC also exhibit unique genetic profiles. It was reported that mutations in TRET promoter, CTNNB1, ARID1A and TP53, CTNNB1, ARID1A are more common in alcohol-related HCC incidences. A recent study identified 5 up-regulated genes (CSMD1, MAGEA3, MAGEA6, CSAG1, and CSAG3) and 4 down-regulated genes (CD5L, UROC1, IGF2, and SLC22A10) that were associated with alcohol-related HCC.

**Exposure To Aflatoxin**

Exposure to aflatoxin B1 (AFB1) is identified as a risk factor for HCC, which is propagated via food contaminations. AFB1 and HBV were proposed to have synergistic interaction. Although the mechanism remains unclear, HBV infection seems to sensitize hepatocytes to the carcinogenic effects of AFB1. AFB1 may trigger carcinogenesis via the transformation to aflatoxin-8, 9-exo epoxide, which interacts with the p53 tumor suppressor gene (Figure 1), and facilitates the mutation at R249S.

Compared to other risk factors, the biomarker for AFB associated HCC was not extensively studied. In addition to TP53, One recent study claimed that frequent mutation in the adhesion G protein coupled receptor B1 (ADGRB1), AXIN1 and TERT were observed in AFB associated HCC cases.

**Non-Alcoholic Fatty Liver Disease And Non-Alcoholic Steatohepatitis**

Non-alcoholic fatty liver disease (NAFLD) is one of the most common risk factors of chronic liver disease in the US, it is frequently associated with cirrhosis, which might lead to HCC. NAFLD represents a variety of chronic liver diseases ranging from hepatic steatosis to the progressed and inflammatory form non-alcoholic steatohepatitis (NASH). In particular, NASH-related HCC incidence increased by 63% from 2002 to 2012 in the US. A study reported that NAFLD and alcohol consumption contributed to steatohepatitis. Together with HCV-NS5A stimulated TLR4-NANOG and the leptin-
Similarly, the missense mutation of the PNPLA3 gene was reported to promote NAFLD/NASH-related HCC. Moreover, one study identified 41 candidate genetic markers for NAFLD associated HCC including Sav1, Son, Slc25a17, Fbxo11, Myo10, and Pten, the mutation seems to promote apoptosis and fibrogenesis.

**Staging Systems**

The severity of cancer is classified by cancer staging systems. A number of systems have been proposed to predict the prognosis of HCC patients, they considered different variables and were tested in varied populations. Therefore, none of the staging schemes has been universally applied. The commonly adopted staging and scoring system for HCC prognosis are the tumor, node, metastasis (TNM), the Okuda stage, the Barcelona Clinic Liver Cancer (BCLC) systems, the Cancer of the Liver Italian Program (CLIP) score, the Japan Integrated Staging scores; CUPI, Chinese University Prognostic Index scores; ALBI, albumin-bilirubin grading system.

| Name  | Country | Stages                  | Reference |
|-------|---------|-------------------------|-----------|
| TNM   | France  | Stage I, II, III         | 118       |
| Okuda | Japan   | Score A, B, C           | 119       |
| BCLC  | Spain   | Score 0-7               | 39        |
| CLIP  | Italy   | Stage 0, A-D            | 120       |
| JIS   | Japan   | Stage I-IV              | 121       |
| CUPI  | Hong Kong | Scores Low-High risk   | 122       |
| ALBI  | Japan   | Grade 1,2,3             | 123       |

**Abbreviations:** TNM, Tumor, Node, Metastasis staging; BCLC, Barcelona Clinic Liver Cancer systems; CLIP, Cancer of the Liver Italian Program (CLIP) score; JIS, Japan Integrated Staging scores; CUPI, Chinese University Prognostic Index scores; ALBI, albumin-bilirubin grading system.

It is generally accepted that diagnosis at an early stage could significantly improve the survival of patients by allowing the implement of curative treatment. Furthermore, the design of treatment strategy is based on the understanding of the cause and stage of each individual. In that sense, diagnosis methods for precision medication should be developed for the identification of HCC at very early stage.

**Early Diagnosis Of HCC**

Diagnosis at an early stage is the key to HCC patient survival. Currently, the most widely used biomarker for HCC diagnosis is serum alpha-fetoprotein (AFP), but its sensitivity and specificity are both around 50%. It is worth noting that liquid biopsy has been extensively developed and put into clinical practice over the past decades. It mainly detects circulating tumor DNA (ctDNA), circulating tumor cell (CTC), exosomes, and circulating tumor RNA (ctRNA) in body liquid including plasma (Figure 2), urine, and cerebrospinal fluid. Among them, ctDNA is the most widely applied genetic biomarker. It is derived from tumor tissue, and carries somatic mutations, CNVs, DNA methylations, viral sequences, and physical characteristics associated with carcinogenesis.

**Somatic Mutations**

The genomic landscape of HCC has been revealed by multiple genome sequencing studies. The three most frequently mutated genes are TERT (40–60%), TP53 (31%), and CTNNB1 (27%). One systematic analysis summarized frequently mutated genes reported, including the tumor suppressor genes AXIN1 (8%) and RB1 (4%), the chromatin remodeling genes ARID1A (7%), ARID2 (5%) and BAP1 (5%), the cellular anti-oxidant defense genes NFE2L2 (3%) and its interactor KEAP1 (5%), Albumin (13%) and 10% APOB mutations. These mutational features were applied in the design of sequencing panels for HCC early screening.

One research group developed a liquid biopsy assay named hepatocellular carcinoma screen (HCCscreen), which could detect HCC in asymptomatic HBsAg-seropositive individuals. The assay simultaneously assesses the ctDNA gene status of TERT, TP53, CTNNB1, and AXIN1, and the level of serum AFP and DCP, as well as the HBV integration profile. In the training cohort, the assay effectively distinguished HCC patients from non-HCC individuals, and the sensitivity and specificity of the assay were 85% and 93% correspondingly. In the validation cohort, the assay showed 100% sensitivity and 94% specificity. Notably, while the training cohort recruited individuals who had liver nodules and/or elevated serum AFP levels, the validation cohort only enrolled individuals with normal serum AFP levels and validated the potential of the HCCscreen to identify early stage HCC.
Another study reported that the TP53 mutation at codon 249 could be used as a biomarker to identify HCC caused by aflatoxin exposure or HBV infection. Its sensitivity and specificity reached 40% and 88% respectively. These results were encouraging in the sense that it provided a method for HCC screening at a very early, or even asymptomatic stage.

DNA Methylations
The alteration of DNA methylation status is an early event in carcinogenesis, so it is also considered as a potential biomarker for HCC early detection. One study developed an HCC-specific methylation marker panel and built a diagnostic prediction model with ten markers. The sensitivity and specificity of the model were 85.7% and 94.3% in the training cohort (715 HCC patients and 560 non-HCC individuals), and 83.3% and 90.5% in the validation cohort (383 HCC patients and 275 non-HCC individuals). Furthermore, the model could effectively distinguish HCC induced by varied risk factors. Another study performed by Abderrahim Oussalah et al evaluated the accuracy of a PCR-based cfDNA assay for SEPT9 promoter methylation. The area under the receiver operating characteristic curve was 0.944, showing it could be served as a potential biomarker for HCC diagnosis.

Physical Characteristics
The physical characteristics of ctDNA are different from non-tumor-derived cfDNA in the aspects of size profiles and preferred end coordinates. Dennis Lo et al performed a detailed analysis of the size profiles of plasma DNA in patients with HBV induced HCC and healthy controls. The results showed that aberrantly short or long DNA molecules existed in the plasma of HCC patients. The short DNAs preferentially carried the tumor-associated copy number aberrations. Moreover, they revealed specific end coordinates of tumor-associated plasma DNA. By calculating the ratio of sequence with tumor-associated DNA ends versus sequence without the characteristic, the possibility of carrying HCC can be estimated, and the area under the receiver operating curve was 0.88.

CTCs, Exosomes And ncRNAs
CTCs are derived from advanced tumors, they may promote tumor metastasis. In a meta-analysis study, the pooled sensitivity and specificity of CTC for the detection of tumor were 67% and 98% respectively. Similarly, tumor-derived exosomes were shown to deliver onco-genes, pathogens and microRNAs. It was reported that a number of exosomal proteins, RNAs and miRNAs may serve as biomarkers for HCC including miR-122, miR-21, and miR192. Consistently, Huang et al performed a systematic review and meta-analysis of published studies to evaluate the utility of microRNAs (miRNAs) in the early diagnosis of HCC. They analyzed 50 studies that included 3423 cases of HCC, 2403 chronic hepatic disease (CH) patients, and 1887 healthy controls. It showed that miRNA could be used as a marker to discriminate HCC.
patients from healthy individuals, and the sensitivity and specificity were 75.8% and 75.0% correspondingly. LncRNAs (long non-coding RNAs) are non-coding mRNA-like transcripts that are longer than 200 nucleotides. Many novel LncRNAs were proposed to be predictive biomarkers for cancer diagnosis or prognosis, including HULC, HOTAIR, MALAT1, and H19. In the case of HCC, lnc-Myd88 was suggested to be a new diagnostic and therapeutic target for HCC because it could increase Myd88 expression, which in turn activates NF-kB and PI3K/AKT signaling pathways.

Prognosis And Post-Operational Monitoring Of HCC

The primary treatment strategy for HCC is to remove the tumor by surgery, but HCC may relapse after the operation. It was reported that the 5-year recurrence rate of HCC after surgery was 74.2% in Japan and Korea. Therefore, post-operative monitoring and precise prognosis are necessary for cancer treatment. Genetic sequencing might be an alternative tool for cancer post-operative monitoring. For example, ALB1 mutation was observed in recurrent liver cancer, the time that the mutation can be detected in ctDNA is associated with the time when the HCC relapses. A unique mutation of HCK p.V174M was also observed in recurrent HCC and metastatic HCC, which was diminished after surgery but would increase rapidly if HCC relapses. Similarly, the IL-28B (rs8099917) TT genotype was interrelated with HCC recurrence. Taken those facts together, genetic sequencing may serve as an important tool for the post-operational surveillance of cancer.

Genetic testing also serves as a useful tool for HCC prognosis evaluation. A number of studies have identified biomarkers associated with the prognosis of HCC, such as miR-203, ATXN7, and Alpha-1-fucosidase. A study demonstrated that the concentration of HMGB1 in blood was linked to prognosis of patients with HCC after receiving sorafenib treatment for 4 weeks. In addition, it was reported that the profile of circulating tumor DNA in blood samples of HCC patients could reveal the heterogeneity of tumors and monitor the process of disease in real time.

Targeted Therapy Of HCC

U.S Food and Drug Administration has approved 7 drugs for HCC treatment (Table 2), which were applied for targeted therapy or immunotherapy. Sorafenib, lenvatinib, regorafenib, ramucirumab and cabozantinib are inhibitors of receptor tyrosine kinase (TK). These drugs can suppress the activities of major TKs including vascular endothelial growth factor receptors (VEGFR1-3), platelet-derived growth factor receptor β (PDGFR-β) and fibroblast growth factor receptors 1–4 (FGFR1-4), thereby inhibiting the growth of tumor cell by antiangiogenic effects. HCC is majorly supplied by hepatic arteries whereas liver parenchymas are supported primarily by portal vein. In fact, radio-graphically visible tumors rely entirely on the oxygen and nutrients supply via hepatic vasculature. Therefore, one of the strategy applied in HCC treatment is to target the angiogenesis pathways.

As the first drug that has been shown to increase the overall survival of patients with liver cancer, sorafenib inhibits the serine/threonine kinases that are the crucial components of the Raf/MEK/ERK pathway (Figure 3). Moreover, the drug could suppress the activity of vascular endothelial growth factor receptors (VEGFR1-3) and platelet-derived growth factor receptor β (PDGFR-β), thereby inhibiting the growth of tumor cell. Consistently, a phase III clinical trial named SHARP demonstrated that sorafenib significantly

| Drug          | Application | Approval Time | Target                                           | Reference |
|---------------|-------------|---------------|--------------------------------------------------|-----------|
| Sorafenib     | First-line  | 2007          | VEGFR1-3 and PDGFR                                | 62        |
| Lenvatinib    | First-line  | 2018          | VEGFR1-3,FGFR1-4, PDGFR-α, KIT and RET            | 71        |
| Regorafenib   | Second-line | 2017          | VEGFR1-3, c-TK112E-2, PDGFR-β, FGFR-1, RET, c-RAF, BRAF and p38MAP kinase | 75        |
| Cabozantinib  | Second-line | 2019          | VEGFR, MET, and AXL                               | 78        |
| Ramucirumab   | Second-line | 2019          | VEGFR-2                                           | 97        |
| Nivolumab     | Second-line | 2017          | Human immunoglobulin G4 anti-PD-1 monoclonal antibody | 124       |
| Pembrolizumab | Second-line | 2018          | PD-1 check point                                  | 91        |

Abbreviations: FGFR, fibroblast growth factor receptor; VEGFR, vascular endothelial growth factor receptor; PDGFR, platelet-derived growth factor receptor; PD-1, programmed cell death protein 1.
improved the median survival time (mOS) of the patients compared with the placebo (10.7 months vs 7.9 months). A trial in the Asia-Pacific region also showed that sorafenib extended the mOS of patients to 6.5 months, whereas the mOS of the placebo group was 4.2 months.

Lenvatinib was discovered by the Tsukuba Research Laboratory in Japan as an angiogenesis inhibitor, it is a multiple receptor tyrosine kinase inhibitor that targets vascular endothelial growth factor receptors (VEGFR1-3), fibroblast growth factor receptors (FGFR1-4), PDGFRα, KIT and RET. Lenvatinib blocks the VEGF pathway and inhibits angiogenesis, exerting anti-tumor activity (Figure 3). The drug has been tested in Phase II and Phase III trials for the treatment of advanced HCC. The phase III trial showed that lenvatinib is comparable to sorafenib in terms of OS. In addition, the incidence of fatal adverse events associated with lenvatinib treatment (including liver failure, cerebral hemorrhage, and respiratory failure) was 2%, which is higher compared to sorafenib (1%).

A series of studies showed that lenvatinib could be an alternative first-line treatment for patients with advanced-stage HCC. In August 2018, the US FDA approved lenvatinib as a first-line therapy for advanced liver cancer. Cabozantinib inhibits tyrosine kinases (Figure 3), including vascular endothelial growth factor receptors 1, 2, 3, MET, and AXL. It is a more potent inhibitor of MET, AXL, RET, FLT3, and Tie2 compared to sorafenib. VEGF, MET, and AXL are involved in tumor proliferation and angiogenesis, thereby cabozantinib can inhibit tumor growth. Abou-Alfa et al showed that among patients who have been treated for HCC, the overall survival was 10.2 months in cabozantinib treated group, and the overall survival of the placebo group was 8.0 months. Moreover, the median progression-free survival was 5.2 months in the cabozantinib treated group whereas

**Figure 3** Pathways and molecules inhibited by sorafenib, regorafenib, cabozantinib, ramucirumab and lenvatinib. Red Xs indicate inhibition by sorafenib, blue Xs indicate inhibition by regorafenib, yellow Xs indicate inhibition by cabozantinib, green Xs indicate inhibition by lenvatinib, and purple Xs indicate inhibition by ramucirumab.

**Abbreviations:** ERK, extracellular signal-regulated kinase; MEK, mitogen-activated protein kinase; Raf, RAF proto-oncogene serine/threonine-protein kinase; Ras, Ras GTPases; FGFR, fibroblast growth factor receptor; VEGFR, vascular endothelial growth factor receptor; PDGFR, platelet-derived growth factor receptor; RTKs, receptor tyrosine kinase; PDGFRα, platelet-derived growth factor receptor α; EGFR, epidermal growth factor receptor; PI3K, phosphoinositide 3-kinase; Mcl-1, induced myeloid leukemia cell differentiation protein; eIF4E, eukaryotic translation initiation factor 4E.
that of the placebo group was 1.9 months. These results showed that cabozantinib could improve the overall survival of patients who were intolerant to or had progressive disease after sorafenib treatment.

**Biomarkers For Targeted Therapy**

Therapeutic effects of drugs might be estimated based on the genetic profiles of patients. Yeon-Su Lee et al identified a total of 1813 genomic variations associated with sorafenib responsiveness, 708 of which located within regions transcribing genes associated with sorafenib responsiveness. These genes are involved in drug absorption, distribution, and drug metabolism pathway. Another study that focused on precision medicine reported that the mutation in RSK2 led to the lasting activation of RAS, which was associated with HCC resistance to sorafenib. Moreover, Teufel et al reported 9 plasma miRNAs and 49 variants in 27 oncogenes or tumor suppressor genes, these miRNA and mutations might be used to identify HCC patients that are most likely to respond to regorafenib. In terms of targeted therapy by antibodies, data suggested that the growth of HCC cells harboring FGF or CCND1 amplification were selectively inhibited by the anti-FGF19 antibody 1A6.

**Immunotherapy Of HCC**

**Immune Microenvironment Of The Liver**

Various types of immune cells reside in the liver and produce different cytokines and growth factors in response to local stimulation. As the result, the immune cell repertoire built up an immune microenvironment that maintains the balance between immune tolerance and immune activation in the liver. The key components of the immune repertoire are macrophages, dendritic cells, myeloid-derived suppressor cells, natural killer (NK) cells, NK T cells, T cells and B cells. By single cell RNA sequencing, studies have identified subsets of immune cells that may conduct distinct immune functions. Two populations of intrahepatic CD68+ macrophages were observed in liver, one was characterized as inflammatory macrophages while the other was suggested to be tolerogenic. Similarly, the T cell and B cell population can be further divided to subsets that expressing various gene markers, including CD3+ γδ T cells and phasphoantigen-reactive γδ T cells, antigen inexperienced B cells as well as plasma B cells. The heterogeneity of intrahepatic immune cell subsets was confirmed by another single cell RNA sequencing study, which discovered CD163 + VSIG4 + Kupffer cells, MS4A1 + CD37 + subset of B cells, and CD56- and CD56 + CD8A + NKT cells. Based on the characterization of the immune microenvironment, HCC patients can be subdivided to high, medium or low immunity groups for prognosis prediction. It was reported that patients with high immunity exhibited poorly cytokeratin 19 (CK19)+, and/or Sal-like protein 4 (SALL4)+ high-grade HCC, which was associated with significantly better prognosis. The medium and low immunity groups were suggested to adapt distinct treatment strategies for better outcomes. Therefore, the efficacy of immunotherapy was partially determined by the immune microenvironment of individuals.

**Immunotherapy**

Immunotherapy has been extensively studied in the past decades, and has made significant progress in the field of cancer therapy. By targeting the immune checkpoint receptors or ligands including cytotoxic T lymphocyte antigen 4 (CTLA-4), programmed cell death protein 1 (PD-1), and programmed cell death 1 ligand 1 (PD-L1), immunotherapy breaks immune tolerance and delays tumor progression.

CTLA-4 is mainly expressed on the surface of activated T cells and regulates the activation of T lymphocytes at the early stages of the tumor immune cycle (Figure 4). By binding to ligand B7-1/B7-2, and CTLA-4 suppresses the activity of T cells and facilitates tumor immune escape.

CTLA-4 is mainly expressed on the surface of activated T cells and regulates the activation of T lymphocytes at the early stages of the tumor immune cycle (Figure 4). By binding to ligand B7-1/B7-2, and CTLA-4 suppresses the activity of T cells and facilitates tumor immune escape (137). CTLA-4 antibodies can block the interaction between CTLA-4 and B7-1/B7-2, promote the binding of B7 to the stimulatory receptor CD28 and restore the activity of T cells.

PD-1 is mainly expressed on the surface of immune cells in peripheral tissues, especially in the tumor microenvironment. It was an unexpected discover when studying T cell apoptosis. PD-1 was later identified as a receptor that negatively regulates the immune response. The PD-1 ligands PD-L1 and PD-L2 were discovered in 2000. Studies have shown that PD-1 and PD-L2 can block T cell activation, proliferation and the production of cytokines, such as interferon-γ (IFN-γ), thereby exerting a negative immune-modulatory effect which results in immunosuppression. Receptor PD-1 on the surface of T lymphocytes binds to PD-L1 on the surface of tumor cells to attenuate the immune responses and inhibits tumor cell elimination by T lymphocytes in the tumor bed.
Therefore, blocking the PD-1/PD-L1 interaction can alleviate tumor-induced immunosuppression and restore the body’s immune activity.

Based on a series of clinical trials (Supplementary Table 1) including CheckMate 057, CheckMate 040,90 KEYNOTE-224,91 and KEYNOTE-042, both nivolumab and pembrolizumab were approved by the FDA for treatment of patients with HCC who have been previously treated with sorafenib.

**Biomarkers For Immunotherapy**

The efficacy of immunotherapy can be predicted by genetic markers. A recent study has shown that low PD-L1 expression is associated with poor clinical outcomes in respond to immunotherapy. The objective clinical responses were observed in 26% (9/34) of patients with PD-L1 expressed in at least 1% of their tumor cells. In contrast, among patients carrying tumor cells with less than 1% of PD-L1 expression, only 19% (26/140) of them responded to ICB treatment.90 On a larger scale, high tumor mutation burden (TMB) is an emerging biomarker that reflects the sensitivity of patients to immune checkpoint inhibitors. TMB measured by hybrid capture-based NGS interrogating 1.2 Mb of the genome can predict clinical outcomes of anti-PD-1/PD-L1 immunotherapy in many tumor types.92 One study has shown that HCC patients with Wnt-β-catenin pathway mutations responded poorly to immune checkpoint blockers. All patients experienced disease progression after treatment, and their median survival was significantly shorter than the patients without the aforementioned mutations (9.1 months vs 15.2 months).93 Despite the fact that the incidence of high microsatellite instability (MSI-H) in HCC is estimated to be low,94 the FDA has approved pembrolizumab for the treatment of advanced-stage cancers with MSI-H regardless of the origin of the cancer.95 Collectively, these results implicate that specific DNA mutations may serve as biomarkers for ICB response prediction.

**Clinical Trials For HCC Treatment**

Clinical trials have been conducted to assess the performance of targeted therapy and immune therapy for HCC treatment. Several large-scale on-going trials focus on the FDA approved drugs for targeted therapy. Sorafenib and lenvatinib have been approved by the FDA as the first-line treatment for HCC patients whose disease cannot be removed by surgery. Notably, recent phase III trial confirmed that lenvatinib was non-inferior to sorafenib in overall survival in untreated HCC (NCT01761266), the progression free survival (7.4 vs 3.7 months, median)
and time to progression (8.9 vs 3.7 months, median) of the lenvatinib group were both better than the sorafenib group. The trial (NCT01908426) that enrolled 707 participants has reported that cabozantinib could lead to longer overall survival and progression-free survival than placebo in patients with previously treated advanced HCC. The median overall survival and progression-free survival were extended to 10.3 months and 5.2 months respectively, with the objective response rate of 4%. Similarly, a trial involving 1000 participants for regorafenib is also underway (NCT03289273). Interestingly, a monoclonal antibody named ramucirumab was applied in targeted therapy as a vascular endothelial growth factor receptor 2 (VEGFR2) inhibitor. The results showed that ramucirumab significantly improved the median overall survival and progression free survival compared to the placebo group. At the median follow-up of 7.6 months, the median overall survival and progression free survival reached 8.5 months and 2.8 months correspondingly.

Numerous data were generated from clinical trials with drugs that have not been approved by FDA. Apatinib, a reversible dual tyrosine kinase inhibitor that selectively targets and inhibits HER2 and EGFR, is tested against placebo in a phase III clinical trial (NCT02329860). The preliminary results showed that 50% patients survived longer that 11.4 months following apatinib administration. The stable disease rate (40.9%) was considerably higher than the progressive disease rate (18.2%). Furthermore, the highly selective FGFR4 inhibitor BLU-554 (NCT02508467), the ATP-competitive cyclin A/CDK2 inhibitor milciclib (NCT03109886) and the dual TORC1/TORC2 inhibitor ATG-008 (NCT03591965) were also tested against HCC. The primary results suggest that BLU-554 might be selective for FGFR1 IHC-positive HCC. No conclusions have been drawn for milciclib and ATG-008.

Nivolumab (Opdivo) and pembrolizumab (Keytruda) were widely applied in clinical trials of immunotherapy. CheckMate-040 (NCT01658878) had confirmed that nivolumab induced active responses in patients with advanced HCC. The follow-up of CheckMate 459 was announced on ESMO 2019 congress, which reported that clinical benefits following nivolumab treatment were observed in predefined subgroups including hepatitis infection status, regions (Asia vs non-Asia), and vascular invasion/metastasis status. However, the Bristol-Myers Squib announced in June 2019 that the randomized Phase 3 study evaluating Opdivo (nivolumab) versus sorafenib as a first-line treatment in patients with unresectable HCC failed to achieve statistical significance for its primary endpoint of overall survival (OS) per the pre-specified analysis. Similarly, the KEYNOTE-224 trial (NCT02702414) reported that pembrolizumab is effective in HCC patients previously treated with sorafenib. The primary result of KEYNOTE-240 was released on 2019 ASCO, which showed that pembrolizumab improved progression free survival over placebo. However, the comparisons were not statistically significant according to the prespecified statistical criteria.

Ipilimumab (Yervoy) is an inhibitor targeting CTLA-4. Concurrent clinical trials primarily focused on the combined effects of ipilimumab and nivolumab. The follow-up of CheckMate-040 reported that the combination obtained meaningful clinical responses, the result of arm A showed that the median overall survival was extended to 23 months.

**Combination Of Treatments**

The combined application of targeted therapy, immunotherapy or locoregional therapy may give rise to great clinical outcomes. A trial in the US assessed the combined effect of sorafenib and carotuximab (TRC105), an antibody against an important angiogenic target named endoglin. The primary results indicated that TRC205+ sorafenib may give rise to additional activity regarding the treatment of advanced/metastatic HCC. A follow-up trial with the same combination is on-going, the combined effect of target therapy and immunotherapy is very promising and the outcome is expected in 2020 (NCT02560779). Another on-going multi-center study is testing the combined efficacy of nivolumab and a novel transforming growth factor beta receptor I kinase inhibitor named galunisertib. The study aimed to include 100 participants and finish in December 2019 (NCT02423343). Similarly, the effect of lenvatinib in combination with pembrolizumab as first-line treatment for HCC is tested in 750 participants, and the multi-centered, phase III trial would be completed in 2022 (NCT03713593). The efficacy of such combinations were confirmed by the primary result of one clinical trial (NCT03289533), which exhibited that the combined use of avelumab and axitiib reduced the sizes of tumors in more than 68% of patients.

Regarding the combination of immunotherapies, AstraZeneca sponsored a global phase III trial that aimed to enroll 1310 patients for the assessment of durvalumab plus tremelimumab as first-line HCC treatment (NCT03298451). The trial was designed based on the promising results of a
previous study, which reported that the combined treatment of durvalumab and tremelimumab showed positive clinical activity in 70% of uninfected HCC patients at ≥16 weeks follow-up.\textsuperscript{106}

Targeted therapy is also combined with locoregional treatment. One clinical trial (NCT03838796) in China involved 482 HCC patients for the observation of the effect of lenvatinib combined with transcatheter arterial chemoembolization (TACE), and the primary study might be completed in 2021 (NCT03838796). Another clinical trial revealed that TACE plus radiofrequency ablation achieved superior efficacy compared to TACE alone, the median overall survival was improved to 29 months whereas that of the TACE group was 18 months.\textsuperscript{107}

**Geographic Distribution Of Clinical Trials In Relation To HCC Incidence Rates**

To overview the geographic distribution of clinical trials, 96 on-going clinical trials for HCC treatment were summarized in Supplementary Table 2 and tagged onto the HCC incidence world map, in which the HCC incidence rate was reflected by color intensity (Figure 5). It appears that the high HCC incidence rates were mostly observed in East Asian and African countries according to the latest global cancer statistics,\textsuperscript{1} however, the clinical trials for HCC treatments were conducted majorly in developed regions including America and European countries. In addition, China also has an increasing number of trials initiated in recent years. It is not unexpected that most clinical trials were planned in regions with good medical care and research facilities. Nevertheless, regions with high incidence rates would have more potential participants for clinical trials, and it would be beneficial for the patients if they can sign up for clinical trials at accessible locations.

**Treatment Strategies Received Varied Clinical Responses In Different Cancer**

Being the effective PD-1 inhibitor antibodies, nivolumab and pembrolizumab are widely applied in the treatment of various malignant tumors including lung cancer and melanoma. The results of CheckMate 017 and 057 showed that nivolumab significantly extended the overall survival of squamous and nonsquamous non-small-cell lung cancer (NSCLC) patients while exhibiting lower symptom burden,\textsuperscript{44,108} which accelerated the approval of nivolumab for the treatment of NSCLC. A 5-year follow-up study reported that the median OS of NSCLC patients received nivolumab second-line treatment was 9.9 months (95% CI, 7.8 to 12.4), with the 5-year survival rate of 16%. Comparing to the low survival rate of patients with metastatic lung cancer, the clinical outcome of nivolumab treatment was considered as a milestone in the advancement of lung cancer treatment.\textsuperscript{109} FDA approved nivolumab for advanced melanoma treatment in 2014. The recently published result of CheckMate 172 revealed that the median overall survival was 25.3–25.8 months for acral or non-

![Figure 5](https://example.com/figure5.png)
apart from immunosuppressive function of the liver. The resident immune cells subsets exhibit varied and complex immune functions, which were not fully understood. Moreover, the inter- and intra-tumor heterogeneity of HCC immune microenvironment was also believed to be the reason that the efficacy of immunotherapy appeared to be unsatisfactory. Apart from immunotherapy, chemotherapies are also limitedly applied in HCC treatment because of the adverse events and toxicities. A clinical trial applied doxorubicin and PIAF for HCC chemotherapy, PIAF showed better responsiveness (10.5% vs 20%), however, 82% patients experienced neutropenia and 57% patients suffered from thrombocytopenia. More importantly, the prognosis of the patients remained poor. The choice of treatment strategy for HCC has been limited, clinical targets that used in other liver disease was also not effective in HCC clinical trials. For example, the Ligand-activated nuclear receptor peroxisome proliferator-activated receptor alpha (PPARα) was a good clinical target for NASH/NAFLD, but it was not clear yet whether it may benefit HCC treatment. Given the facts above, it seems that finding a safe and efficient treatment for HCC still remains a global challenge nowadays.

Conclusion
HCC patients often exhibit varied genetic profiles, and these differences can be applied in the early screening of HCC and prognosis prediction by genetic markers. In relation to diagnosis, differed treatment strategy can be designed for precision medicine, and potential biomarkers may be utilized to predict responses to drugs. Moreover, genetic markers were involved in the post-operational surveillance of HCC, which provides evidence of tumor reoccurrence at asymptomatic state. Apart from established treatment strategies, clinical trials for the investigation of new treatment plans were conducted globally. Although geographic disparity was observed, these studies enlightened new paths for HCC treatment, which would significantly improve patient survival. The results of the clinical trials suggest that the efficacy of immunotherapy in HCC is not desirable compared to lung cancer or melanoma. The underlying barrier would be the heterogeneity of the immune microenvironment of the liver. Given the above, studies on the immune microenvironment of the liver and the understanding of its heterogeneity are required for the improvement of HCC treatment efficacy.

Acknowledgment
The work received financial support from the Bureau of Industry and Information Technology of Shenzhen, programme grant 20170922151538732.

Author Contributions
All authors contributed to data analysis, drafting or revising the article, gave final approval of the version to be published, and agree to be accountable for all aspects of the work.

Disclosure
Yuling Wu, Jiajia Zhang, Zhichao Fu, Tieshan Feng, Ming Liu, Jie Han, and Shifu Chen are affiliated with HaploX Biotechnology Co. Ltd. The authors report no other conflicts of interest in this work.

References
1. Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2018;68(6):394–424. doi:10.3322/caac.21492
2. Boyle DA. Hepatocellular carcinoma: implications for Asia-Pacific oncology nurses. Asia Pac J Oncol Nurs. 2017;4(2):98–103. doi:10.4103/2347-5625.204497
3. Yang JD, Roberts LR. Hepatocellular carcinoma: a global view. *Nat Rev Gastroenterol Hepatol*. 2010;7(8):448–458. doi:10.1038/nrgastro.2010.100

4. Balogh J, Victor D 3rd, Asham EH, et al. Hepatocellular carcinoma: a review. *J Hepatocell Carcinoma*. 2016;3:41–53. doi:10.2147/JHC.S61146

5. Fattovich G, Stroffolini T, Zagni I, Donato F. Hepatocellular carcinoma in cirrhosis: incidence and risk factors. *Gastroenterology*. 2004;127(5 Suppl 1):S35–S50. doi:10.1053/j.gastro.2004.09.014

6. Frank A, Seitz HK, Bartsch H, Frank N, Nair J. Immunohistochemical detection of 1N6-ethenedeoxyadenosine in nuclei of human liver affected by diseases predisposing to hepato-carcinogenesis. *Carcinogenesis*. 2004;25(6):1027–1031. doi:10.1093/carcin/bgh089

7. O’Rourke JM, Sagar VM, Shah T, Shetty S. Carcinogenesis on the background of liver fibrosis: implications for the management of hepatocellular cancer. *World J Gastroenterol*. 2018;24(39):4436–4447. doi:10.3748/wjg.v24.i39.4436

8. Zhu RX, Seto WK, Lai CL, Yuen MF. Epidemiology of hepatocellular carcinoma in the Asia-Pacific region. *Gut Liver*. 2016;10(3):332–339. doi:10.5009/gnl15257

9. Summers J, Mason WS. Replication of the genome of a hepatitis B virus (HBV) on cell-growth inhibition in a CCL13-HBx stable cell line. *Intervirology*. 2008;51(1):26–32. doi:10.1159/000118793

10. Arzamanan A, Reis HM, Feitelson MA. Pathogenic mechanisms in HBV- and HCV-associated hepatocellular carcinoma. *Nat Rev Cancer*. 2013;13(2):123–135. doi:10.1038/nrm3449

11. Lee CF, Ling ZQ, Zhao T, Lee KR. Distinct expression patterns in hepatitis B virus- and hepatitis C virus-infected hepatocellular carcinoma. *World J Gastroenterol*. 2008;14(39):6072–6077. doi:10.3748/wjg.v14.i40.6072

12. Patil IA, Lee SA, Macias E, et al. Role of cyclin D1 as a mediator of c-Met- and beta-catenin-induced hepatocarcinogenesis. *Cancer Res*. 2009;69(1):253–261. doi:10.1158/0008-5472.CAN-08-2514

13. Hung JH, Teng YN, Wang LH, et al. Induction of Bcl-2 expression by hepatitis B virus pre-S2 mutant large surface protein resistance to 5-fluorouracil treatment in Huh-7 cells. *PLoS One*. 2011;6(12):e28977. doi:10.1371/journal.pone.0028977

14. He Y, Zhang H, Yin J, et al. I kappaBalpha gene promoter polymorphism is associated with hepatocarcinogenesis in patients infected with hepatitis B virus genotype C. *Carcinogenesis*. 2009;30(11):1916–1922. doi:10.1093/carcin/bgp226

15. Lu JW, Hsia Y, Yang WY, et al. Identification of the common regulators for hepatocellular carcinoma induced by hepatitis B virus X antigen in a mouse model. *Carcinogenesis*. 2012;33(1):209–219. doi:10.1093/carcin/bg224

16. Kan Z, Zheng H, Liu X, et al. Whole-genome sequencing identifies recurrent mutations in hepatocellular carcinoma. *Genome Res*. 2013;23(9):1422–1433. doi:10.1101/gr.154942.113

17. Ghouri YA, Mian I, Rowe JH. Review of hepatocellular carcinoma: epidemiology, etiology, and carcinogenesis. *J Carcinog*. 2017;16:1. doi:10.4103/jcar.Jcar_9_16

18. Parkin DM. The global health burden of infection-associated cancers in the year 2002. *Int J Cancer*. 2006;118(12):3030–3044. doi:10.1002/ijc.21731
54. Kim DS, Kim BW, Hatano E, et al. Surgical outcomes of hepatoce-
   lular carcinoma: a multicenter, open-label, phase II safety study.
   Clin Cancer Res. 2018;24(1):243–250. doi:10.1159/000452511

55. Cai ZX, Chen G, Zeng YY, et al. Prospects of noncoding RNAs in
   hepatocellular carcinoma. Biomed Res Int. 2018;2018:6579436.
   doi:10.1155/2018/6579436

56. Xu X, Yin Y, Tang J, et al. Long non-coding RNA Mdy88
   promotes growth and metastasis in hepatocellular carcinoma via
   regulating Mdy88 expression through H3K27 modification. Cell
   Death Dis. 2017;8(10):e3124. doi:10.1038/cddis.2017.318

57. Ye SL, Yang J, Bie P, et al. Safety assessment of sorafenib in
   Chinese patients with unresectable hepatocellular carcinoma: sub-
   group analysis of the GIDEON study. BMC Cancer. 2018;18
   (1):247. doi:10.1186/s12885-018-4242-8

58. Cai ZX, Chen G, Zeng YY, et al. Circulating tumor DNA profil-
   ing reveals clonal evolution and real-time disease progression in
   advanced hepatocellular carcinoma. Int J Cancer. 2017;141
   (5):977–985. doi:10.1002/ijc.30798

59. Hodo Y, Honda M, Tanaka A, et al. Association of interleukin-
   28B genotype and hepatocellular carcinoma recurrence in patients
   with chronic hepatitis C. Clin Cancer Res. 2013;19(7):1827–
   1837. doi:10.1158/1078-0432.CCR-12-1641

60. Han C, Yu L, Liu X, et al. AXINN7 gene variants and expression
   predict post-operative clinical outcomes in hepatitis B virus-
   related hepatocellular carcinoma. Cell Physiol Biochem. 2016;39
   (6):2427–2438. doi:10.1159/000452511

61. Liu WM, Zhang M, Wang F, et al. ATP502 is a potential bio-
   marker for prediction of sorafenib efficacy in hepatocellular carci-
   noma. Tumor Biol. 2016;37(5):5609–5617. doi:10.1007/s13277-
   015-3606-0

62. Llovet JM, Ricci S, Mazzaferro V, et al. Sorafenib in advanced
   hepatocellular carcinoma. N Engl J Med. 2008;359(4):378–390.
   doi:10.1056/NEJMoa078857

63. Matsuki M, Hoshi T, Yamamoto Y, et al. Lenvatinib inhibits
   angiogenesis and tumor fibroblast growth factor signaling path-
   ways in human hepatocellular carcinoma models. Cancer Med.
   2018;7(6):2641–2653. doi:10.1002/cam4.1517

64. Sauret-Bianchi A, Siena S, Tonini G, Bardelli A, Santini D.
   Overcoming dynamic molecular heterogeneity in metastatic col-
   orectal cancer: multikinase inhibition with regorafenib and the
   case of rechallenge with anti-EGFR. Cancer Treat Rev. 2016;
   51:54–62. doi:10.1016/j.ctrv.2016.10.006

65. Xiang Q, Chen W, Ren M, et al. Cabozantinib suppresses tumor
   growth and metastasis in hepatocellular carcinoma by a dual
   blockade of VEGFR2 and MET. Clin Cancer Res. 2014;20
   (11):2959–2970. doi:10.1158/1078-0432.CCR-13-2620

66. Carmeliet P. VEGF as a key mediator of angiogenesis in cancer.
   Oncology. 2005;69(Suppl 3):4–10. doi:10.1159/000088478

67. Wilhelm SM, Carter C, Tang L, et al. BAY 43-9006 exhibits
   broad spectrum oral antitumor activity and targets the RAF/
   MEK/ERK pathway and receptor tyrosine kinases involved in
   tumor progression and angiogenesis. Cancer Res. 2004;64
   (19):7099–7109. doi:10.1158/0008-5472.CAN-04-1443

68. Rollmann S, Santoro A. Sorafenib therapy in advanced hepa-
   tocellular carcinoma: the SHARP trial. Expert Rev Anticancer
   Ther. 2009;9(6):739–745. doi:10.1586/era.09.41

69. Keating GM. Sorafenib: a review in hepatocellular cancer.
   Target Oncol. 2017;12(2):243–253. doi:10.1007/s11523-017-
   0484-7

70. Kado M. Extremely high objective response rate of lenvatinib: its
   clinical relevance and changing the treatment paradigm in hepa-
   tocellular carcinoma. Liver Cancer. 2018;7(3):215–224. doi:
   10.1159/000492533

71. Kado M, Finn RS, Qin S, et al. Lenvatinib versus sorafenib in first-
   line treatment of patients with unresectable hepatocellular carci-
   noma: a randomised phase 3 non-inferiority trial. Lancet. 2018;
   391(10126):1163–1173. doi:10.1016/S0140-6736(18)30207-1

72. Ikeda K, Kudo M, Kawaoze S, et al. Phase 2 study of lenva-
   tinib in patients with advanced hepatocellular carcinoma. J
   Gastroenterol. 2017;52(4):512–519. doi:10.1007/s00535-016-
   1263-4

73. Bruix J, Tak WY, Gasbarrini A, et al. Regorafenib as second-line
   therapy for intermediate or advanced hepatocellular carcinoma:
   multicentre, open-label, phase II safety study. Eur J Cancer.
   2013;49(16):3412–3419. doi:10.1016/j.ejca.2013.05.028
Kelley RK, Abou-Alfa GK, Bendell JC, et al. Phase I/II study of cabozantinib in patients with advanced hepatocellular carcinoma previously treated with sorafenib (KEYNOTE-224): a non-randomised, open-label phase 2 trial. *Lancet Oncol*. 2019;20(7):940–952. doi:10.1016/S1470-2045(18)30351-6

Goodman AM, Kato S, Bazhenova L, et al. Tumor mutational burden as an independent predictor of response to immunotherapy in diverse cancers. *Mol Cancer Ther*. 2017;16(11):2598–2608. doi:10.1158/1535-7163.MCT-17-0386

Pinyol R, Sia D, Llovet JM. Immune exclusion-Wnt(CTNNB1) class predicts resistance to immunotherapies in HCC. *Clin Cancer Res*. 2019;25(7):2021–2023. doi:10.1158/1078-0432.CCR-18-3778

Llovet JM, Montal R, Sia D, Finn RS. Molecular therapies and precision medicine for hepatocellular carcinoma. *Nat Rev Clin Oncol*. 2018;15(10):599–616. doi:10.1038/s41571-018-0073-4

Marcus L, Lemery SJ, Keegan P, Pazdur R. FDA approval summary: pembrolizumab for the treatment of microsatellite instability-high solid tumors. *Clin Cancer Res*. 2019;25(13):3753–3758. doi:10.1158/1078-0432.CCR-18-4070

Llovet JM, Ramucirumab (RAM) for sorafenib intolerant patients with hepatocellular carcinoma (HCC) and elevated baseline alpha fetoprotein (AFP): Outcomes from two randomized phase 3 studies (REACH, REACH2). *J Clin Oncol*. 37;2019(suppl; abstr 4073).

Zhu AX, Finn RS, Galle PR, Kudo M. First-line avelumab + axitinib in patients with advanced hepatocellular carcinoma (HCC): Results from a phase 1b trial (VEGF SOR). *Ann Oncol*. 2019;30(suppl_5):v851–v934. doi:10.1093/annonc/mdz394.029

Segovia-Mendoza M, Gonzalez-Gonzalez ME, Barrera D, Diaz L, Garcia-Beccera R. Efficacy and mechanism of action of the tyrosine kinase inhibitors gefitinib, lapatinib and neratinib in the treatment of HER2-positive breast cancer: preclinical and clinical evidence. *Am J Cancer Res*. 2015;5(9):2531–2561.

Kong Y, Sun L, Hou Z, et al. Apatinib is effective for treatment of advanced hepatocellular carcinoma. *Oncotarget*. 2017;8(62):105596–105605. doi:10.18632/oncotarget.22337

Kim R, Sharma S, Meyer T, et al. First-In-Human Study of BLU-554, a Potent, Highly-Selective FGFR4 Inhibitor Designed for Hepatocellular Carcinoma (HCC) with FGFR4 Pathway Activation. Oxford: Elsevier; 2016.

Yau T, Park JW, Finn RS, et al. CheckMate 459: A randomized, multi-center phase III study of nivolumab (NIVO) vs sorafenib (SOR) as first-line (1L) treatment in patients (pts) with advanced hepatocellular carcinoma (aHCC). *Ann Oncol*. 2019;30(suppl_5):v851–v934. doi:10.1093/annonc/mdz394.029

Finn RS. Results of KEYNOTE-240: phase 3 study of pembrolizumab (Pembro)+best supportive care (BSC) for second line therapy in advanced hepatocellular carcinoma (HCC). *J Clin Oncol*. 37;2019(suppl; abstr 4004).

Yau T. Nivolumab (NIVO) + ipilimumab (IPI) combination therapy in patients (pts) with advanced hepatocellular carcinoma (aHCC): Results from CheckMate040. *J Clin Oncol*. 37;2019(suppl; abstr 4012).

Raghav KPS, Mody K, Greten TF, et al. An open label phase 1b/2 trial of TRC105 and sorafenib in patient with advanced/metastatic hepatocellular carcinoma (HCC) (NCT01806064). *J Clin Oncol*. 2018;36(4_suppl; abstr 301). doi:10.1200/JCO.2018.36.4_suppl.301

Kudo M. First-line avelumab + axitinib in patients with advanced hepatocellular carcinoma: Results from a phase 1b trial (VEGF Liver 100). *J Clin Oncol*. 37;2019(suppl; abstr 4072).

Kelley RK, Abou-Alfa GK, Bendell JC, et al. Phase I/II study of durvalumab and tremelimumab in patients with unresectable hepatocellular carcinoma (HCC): phase I safety and efficacy analyses. *J Clin Oncol*. 37;2017;35(15_suppl; abstr 4073). doi:10.1200/JCO.2017.35.15_suppl.4073
107. Yin X. Randomized clinical trial of transcatheter arterial chemoembolization plus radiofrequency ablation versus transcatheter arterial chemoembolization for hepatocellular carcinoma with intermediate stage (BCLC stage B) hepatocellular carcinoma beyond Milan criteria. J Clin Oncol. 2019(suppl; abstr 4077).

108. Borghaei H, Paz-Ares L, Horan L, et al. Nivolumab versus docetaxel in advanced nonsquamous non-small-cell lung cancer. N Engl J Med. 2015;373(17):1627–1639. doi:10.1056/NEJMoa1507643

109. Gettinger S, Horan L, Jackman D, et al. Five-year follow-up of nivolumab in previously treated advanced non-small-cell lung cancer: results from the CA209-003 study. J Clin Oncol. 2018;36(17):1675–1684. doi:10.1200/JCO.2017.77.0412

110. Nathan P, Ascenso PA, Hanen J, et al. Safety and efficacy of nivolumab in patients with rare melanoma subtypes who progressed on or after ipilimumab treatment: a single-arm, open-label, phase II study (CheckMate 172). Eur J Cancer. 2019;119:168–178. doi:10.1016/j.ejca.2019.07.010

111. Si L, Zhang X, Shu Y, et al. A phase Ib study of pembrolizumab as second-line therapy for Chinese patients with advanced or metastatic melanoma (KEYNOTE-151). Transl Oncol. 2019;12(6):828–835. doi:10.1016/j.tranon.2019.02.007

112. Nosaki K, Saka H, Hosomi Y, et al. Safety and efficacy of pembrolizumab monotherapy in elderly patients with PD-L1-positive advanced non-small-cell lung cancer: pooled analysis from the KEYNOTE-010, KEYNOTE-024, and KEYNOTE-042 studies. Lung Cancer. 2019;135:188–195. doi:10.1016/j.lungcan.2019.07.004

113. Obeid JM, Kunk PR, Zaydfudim VM, Bullock TN, Slingluff CL Jr., Rahma OE. Immunotherapy for hepatocellular carcinoma patients: is it ready for prime time? Cancer Immunol Immunother. 2018;67(2):161–174. doi:10.1007/s00262-017-2082-z

114. Zhang Q, Lou Y, Yang J, et al. Integrated multiomic analysis reveals comprehensive tumour heterogeneity and novel immunophenotypic classification in hepatocellular carcinomas. Gut. 2019. doi:10.1136/gutjnl-2019-318912

115. Deng GL, Zeng S, Shen H. Chemotherapy and target therapy for hepatocellular carcinoma: new advances and challenges. World J Hepatol. 2015;7(5):787–798. doi:10.4254/wjh.v7.i5.787

116. Yeo W, Mok TS, Zee B, et al. A randomized phase III study of doxorubicin versus cisplatin/interferon alpha-2b/doxorubicin/fluorouracil (PIAF) combination chemotherapy for unresectable hepatocellular carcinoma. J Natl Cancer Inst. 2005;97(20):1532–1538. doi:10.1093/jnci/dij315

117. Tanaka N, Aoyama T, Kimura S, Gonzalez FJ. Targeting nuclear receptors for the treatment of fatty liver disease. Pharmacol Ther. 2017;179:142–157. doi:10.1016/j.pharmthera.2017.05.011

118. Denois P, Lacour J, Wolff JP, Weiler J, Michel G. [TNM classification of cancer of the uterine cervix. Apropos of contents and treatment of T2]. J Gynecol Obstet Biol Reprod (Paris). 1972;1(2):161–166.

119. Okuda K, Ohtsuki T, Obata H, et al. Natural history of hepatocellular carcinoma and prognosis in relation to treatment. Study of 850 patients. Cancer. 1985;56(4):918–928. doi:10.1002/1097-0142(19850815)56:4<918::aid-cncr2820560437>3.0.co;2-e

120. The CLIP investigator group. Prospective validation of the CLIP score: a new prognostic system for patients with cirrhosis and hepatocellular carcinoma. The Cancer of the Liver Italian Program (CLIP) Investigators. Hepatology. 2000;31(4):840–845. doi:10.1053/he.2000.5628

121. Kubo S, Tanaka H, Shuto T, et al. Prognostic effects of causative virus in hepatocellular carcinoma according to the Japan integrated staging (JIS) score. J Gastroenterol. 2005;40(10):972–979. doi:10.1007/s00535-005-1681-1

122. Leung TW, Tang AM, Zee B, et al. Construction of the Chinese University Prognostic Index for hepatocellular carcinoma and comparison with the TNM staging system, the Okuda staging system, and the Cancer of the Liver Italian Program staging system: a study based on 926 patients. Cancer. 2002;94(6):1760–1769. doi:10.1002/cncr.10384

123. Johnson PJ, Berhane S, Kagebayashi C, et al. Assessment of liver function in patients with hepatocellular carcinoma: a new evidence-based approach—the ALBI grade. J Clin Oncol. 2015;33(6):550–558. doi:10.1200/JCO.2014.57.9151

124. Finkelmeier F, Waidmann O, Trojan J. Nivolumab for the treatment of hepatocellular carcinoma. Expert Rev Anticancer Ther. 2018;18(12):1169–1175. doi:10.1080/14737314.2018.1535315